Video Coming Soon
...
An IQ working group was founded in 2018 with the goal of revisiting blinding concepts in early clinical trials in healthy volunteers and patients. The working group developed and conducted a survey across multiple biopharmaceutical companies in early 2020 in order to gain information about design options commonly used in early clinical development trials with respect to level of blinding. Sixteen large and mid-size pharmaceutical companies participated in the survey.
